Cohen addresses the three-pronged parts of drug development process or clinical trials
Quintiles released the written remarks, its Senior Vice President and Global Head of Early Clinical Development, Oren Cohen, MD, will make today October 9, to a Congressional Roundtable being held in Research Triangle Park, NC. The roundtable is an outgrowth of the U.S. House Energy & Commerce Committee’s 21st Century Cures Initiative and will focus on the discovery, development, and delivery of vaccines.
In these remarks, again specific to vaccines, Cohen addresses the three-pronged parts of drug development process or clinical trials; pathways or regulatory alternatives to minimize clinical development times, and preparedness for development of vaccines.
Under clinical trials or process, interestingly, Cohen targets ECs and IRB inefficiencies, promotes eSource Data Capture and the enforced use of common data standards, such as those created by CDISC.
Under pathways, Cohen believes an adaptive licensing approach similar to the EMA pilots now underway, would be helpful for FDA in regard to vaccine development.
Dr. Cohen is an infectious diseases expert and head’s Quintiles’ Phase I Clinical Research division, which includes world-class facilities in Overland Park, Kansas (US) and London.
Read the full release here.
The following infographic was sent with the press release. (Click to enlarge).
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.